2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Camm, A. John; Lip, Gregory Y. H.; De Caterina, Raffaeleet al.
2012 • In European Heart Journal, 33 (21), p. 2719-47
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I.C., Widimsky, V.P., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Europace, 12, pp. 1360-1420. , ESC Committee for Practice Guidelines
Connolly, S.J., Eikelboom, J., Joyner, C., Diener, H.C., Hart, R., Golitsyn, S., Flaker, G., Yusuf, S., Apixaban in patients with atrial fibrillation (2011) N Engl J Med, 364, pp. 806-817. , AVERROES Steering Committee and Investigators
Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Califf, R.M., Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation (2011) N Engl J Med, 365, pp. 883-891. , ROCKET AF Investigators
Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Wallentin, L., Apixaban vs. warfarin in patients with atrial fibrillation (2011) N Engl J Med, 365, pp. 981-992. , ARISTOTLE Committees and Investigators
Connolly, S.J., Camm, A.J., Halperin, J.L., Joyner, C., Alings, M., Amerena, J., Atar, D., Hohnloser, S.H., Dronedarone in high-risk permanent atrial fibrillation (2011) N Engl J Med, 365, pp. 2268-2276. , PALLAS Investigators
Wann, L.S., Curtis, A.B., January, C.T., Ellenbogen, K.A., Lowe, J.E., Estes Iii., N.A., Page, R.L., Yancy, C.W., ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) Circulation, 123, pp. 104-123. , 2011 Writing Group Members 2006 Writing Committee Members ACCF/AHA Task Force Members
Wann, L.S., Curtis, A.B., Ellenbogen, K.A., Ezekowitz, M.D., Jackman, W.M., January, C.T., Lowe, J.E., Yancy, C.W., 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American college of cardiology foundation/American heart association task force on practice guidelines (2011) Circulation, 123, pp. 1144-1150. , American College of Cardiology Foundation/American Heart Association Task Force
You, J.J., Singer, D.E., Howard, P.A., Lane, D.A., Eckman, M.H., Fang, M.C., Hylek, E.M., Lip, G.Y., American college of chest physicians Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines (2012) Chest, 141, pp. e531S-e575S
Skanes, A.C., Healey, J.S., Cairns, J.A., Dorian, P., Gillis, A.M., McMurtry, M.S., Mitchell, L.B., Nattel, S., Focused 2012 update of the canadian cardiovascular society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control (2012) Can J Cardiol, 28, pp. 125-136. , Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee
Kirchhof, P., Lip, G.Y., Van Gelder, I.C., Bax, J., Hylek, E., Kaab, S., Schotten, U., Camm, A.J., Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options Executive summary of the report from the 3rd AFNET/EHRA consensus conference (2012) Europace, 14, pp. 8-27
Healey, J.S., Connolly, S.J., Gold, M.R., Israel, C.W., Van Gelder, I.C., Capucci, A., Lau, C.P., Hohnloser, S.H., Subclinical atrial fibrillation and the risk of stroke (2012) N Engl J Med, 366, pp. 120-129. , ASSERT Investigators
Binici, Z., Intzilakis, T., Nielsen, O.W., Kober, L., Sajadieh, A., Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke (2010) Circulation, 121, pp. 1904-1911
Fitzmaurice, D.A., Hobbs, F.D., Jowett, S., Mant, J., Murray, E.T., Holder, R., Raftery, J.P., Allan, T.F., Screening vs. routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial (2007) Br Med J, 335, p. 383
Hobbs, F.D., Fitzmaurice, D.A., Mant, J., Murray, E., Jowett, S., Bryan, S., Raferty, J., Lip, G., A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) vs. routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study (2005) Health Technol Assess, 9, pp. iii-iv. , ix-x, 1-74
Lip, G., What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? (2012) J R Coll Physicians Edinb, 42 (SUPPL. 18), pp. 35-44
Lip, G.Y., Stroke in atrial fibrillation: Epidemiology and thromboprophylaxis (2011) J Thromb Haemost, 9 (SUPPL. 1), pp. 344-351
Wilke, T., Groth, A., Mueller, S., Pfannkuche, M., Verheyen, F., Linder, R., Maywald, U., Bauersachs, R., Oral anticoagulation use by patients with atrial fibrillation in Germany Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients (2012) Thromb Haemost, 107, pp. 1053-1065
Kirchhof, P., Nabauer, M., Gerth, A., Limbourg, T., Lewalter, T., Goette, A., Wegscheider, K., Steinbeck, G., Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions (2011) Thromb Haemost, 105, pp. 1010-1023. , AFNET registry investigators
Lip, G.Y., The role of aspirin for stroke prevention in atrial fibrillation (2011) Nat Rev Cardiol, 8, pp. 602-606
Olesen, J.B., Lip, G.Y., Lindhardsen, J., Lane, D.A., Ahlehoff, O., Hansen, M.L., Raunsø, J., Torp-Pedersen, C., Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study (2011) Thromb Haemost, 106, pp. 739-749
Ogilvie, I.M., Welner, S.A., Cowell, W., Lip, G.Y., Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients (2011) Thromb Haemost, 106, pp. 34-44
Mant, J., Hobbs, F.R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y., Murray, E., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial (2007) Lancet, 370 (9586), pp. 493-503. , DOI 10.1016/S0140-6736(07)61233-1, PII S0140673607612331
Rash, A., Downes, T., Portner, R., Yeo, W.W., Morgan, N., Channer, K.S., A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) (2007) Age and Ageing, 36 (2), pp. 151-156. , DOI 10.1093/ageing/afl129
Friberg, L., Rosenqvist, M., Lip, G.Y., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation Cohort study (2012) Eur Heart J, 33, pp. 1500-1510
Connolly, S.J., Pogue, J., Hart, R.G., Hohnloser, S.H., Pfeffer, M., Chrolavicius, S., Yusuf, S., Effect of clopidogrel added to aspirin in patients with atrial fibrillation (2009) N Engl J Med, 360, pp. 2066-2078
Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Erqou, S., Sattar, N., Ray, K.K., Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials (2012) Arch Intern Med, 172, pp. 209-216
De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Weitz, J.I., New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper (2012) J Am Coll Cardiol, 59, pp. 1413-1425. , Coordinating Committee
Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation (2001) Journal of the American Medical Association, 285 (22), pp. 2864-2870
Karthikeyan, G., Eikelboom, J.W., The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? (2010) Thromb Haemost, 104, pp. 45-48
Keogh, C., Wallace, E., Dillon, C., Dimitrov, B.D., Fahey, T., Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke A systematic review and meta-analysis (2011) Thromb Haemost, 106, pp. 528-538
Lin, L.Y., Lee, C.H., Yu, C.C., Tsai, C.T., Lai, L.P., Hwang, J.J., Chen, P.C., Lin, J.L., Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-A nationwide database analysis (2011) Atherosclerosis, 217, pp. 292-295
Olesen, J.B., Fauchier, L., Lane, D.A., Taillandier, S., Lip, G.Y., Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project (2012) Chest, 141, pp. 147-153
Olesen, J.B., Lip, G.Y., Lane, D.A., Køber, L., Hansen, M.L., Karasoy, D., Hansen, C.M., Torp-Pedersen, C., Vascular disease and stroke risk in atrial fibrillation: A nationwide cohort study (2012) Am J Med, 125, p. 826. , e13-23
Van Walraven, C., Hart, R.G., Connolly, S., Austin, P.C., Mant, J., Hobbs, F.D., Koudstaal, P.J., Singer, D.E., Effect of age on stroke prevention therapy in patients with atrial fibrillation (2009) Stroke, 40, pp. 1410-1416
Olesen, J.B., Lip, G.Y., Hansen, M.L., Hansen, P.R., Tolstrup, J.S., Lindhardsen, J., Selmer, C., Torp-Pedersen, C., Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study Br Med J, 2011, p. 342
Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Prostran, M.S., Lip, G.Y., Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: The belgrade atrial fibrillation study (2012) Circ Arrhythm Electrophysiol, 5, pp. 319-326
Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., Lip, G., The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study (2012) Thromb Haemost, 107, pp. 1172-1179
Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation (2010) Chest, 137, pp. 263-272
Independent predictors of stroke in patients with atrial fibrillation: A systematic review (2007) Neurology, 69, pp. 546-554. , Stroke Risk in Atrial Fibrillation Working Group
Hughes, M., Lip, G.Y.H., Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data (2008) Thrombosis and Haemostasis, 99 (2), pp. 295-304. , http://www.schattauer.de/index.php?id=1871&L=1&no_cache= 1&tx_ivabonnenten_pi5[download]=1&tx_ivabonnenten_pi5[artikel]=22461, DOI 10.1160/TH07-08-0508
Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials (1998) Arch Intern Med, 158, pp. 1316-1320. , AF-Investigators
Banerjee, A., Taillandier, S., Olesen, J.B., Lane, D.A., Lallemand, B., Lip, G.Y., Fauchier, L., Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project (2012) Eur J Heart Fail, 14, pp. 295-301
Friberg, L., Benson, L., Rosenqvist, M., Lip, G.Y., Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study (2012) BMJ, 344, pp. e3522
Avgil Tsadok, M., Jackevicius, C.A., Rahme, E., Humphries, K.H., Behlouli, H., Pilote, L., Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation (2012) JAMA, 307, pp. 1952-1958
Van Staa, T.P., Setakis, E., Di Tanna, G.L., Lane, D.A., Lip, G.Y., A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice (2011) J Thromb Haemost, 9, pp. 39-48
Abu-Assi, E., Otero-Raviña, F., Allut Vidal, G., Coutado Méndez, A., Vaamonde Mosquera, L., Sánchez Loureiro, M., Caneda Villar, M.C., González-Juanatey, J.R., Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation (2011) Int J Cardiol, , on behalf of Grupo Barbanza researchers Published online ahead of print 19 November
Boriani, G., Botto, G.L., Padeletti, L., Santini, M., Capucci, A., Gulizia, M., Ricci, R., Lip, G.Y., Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring (2011) Stroke, 42, pp. 1768-1770. , Italian AT-500 Registry Investigators
Chao, T.F., Lin, Y.J., Tsao, H.M., Tsai, C.F., Lin, W.S., Chang, S.L., Lo, L.W., Chen, S.A., CHADS(2) and CHA (2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation (2011) J Am Coll Cardiol, 58, pp. 2380-2385
Marinigh, R., Lane, D.A., Lip, G.Y., Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk (2011) J Am Coll Cardiol, 57, pp. 1339-1348
Connolly, S.J., Eikelboom, J.W., Ng, J., Hirsh, J., Yusuf, S., Pogue, J., De Caterina, R., Hart, R.G., Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable (2011) Ann Intern Med, 155, pp. 579-586. , ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators
Lip, G.Y., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., Lane, D.A., Kirchhof, Bleeding risk assessment, management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis (2011) Europace, 13, pp. 723-746
Gage, B.F., Yan, Y., Milligan, P.E., Waterman, A.D., Culverhouse, R., Rich, M.W., Radford, M.J., Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF) (2006) American Heart Journal, 151 (3), pp. 713-719. , DOI 10.1016/j.ahj.2005.04.017, PII S0002870305004369
Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J., Lip, G.Y., A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey (2010) Chest, 138, pp. 1093-1100
Fang, M.C., Go, A.S., Chang, Y., Borowsky, L.H., Pomernacki, N.K., De N, U., A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study (2011) J Am Coll Cardiol, 58, pp. 395-401
Cairns, J.A., Connolly, S., McMurtry, S., Stephenson, M., Talajic, M., Canadian Cardiovascular Society atrial fibrillation Guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter (2011) Can J Cardiol, 27, pp. 74-90
Roldan, V., Marin, F., Manzaro-Fernandez, S., Gallego, P., Valdes, M., Vincente, V., Lip, G.Y., Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population (2012) Chest, , Published online ahead of print 21 June doi:10.1378/chest.12-0608
Apostolakis, S., Lane, D.A., Guo, Y., Buller, H.R., Lip, G.Y.H., Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study (2012) J Am Coll Cardiol, 60, pp. 861-867
Lip, G.Y., Frison, L., Halperin, J.L., Lane, D.A., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) score (2011) J Am Coll Cardiol, 57, pp. 173-180
Olesen, J.B., Lip, G.Y., Hansen, P.R., Lindhardsen, J., Ahlehoff, O., Andersson, C., Weeke, P., Torp-Pedersen, C., Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort (2011) J Thromb Haemost, 9, pp. 1460-1467
Gallego, P., Roldán, V., Torregrosa, J.M., Gálvez, J., Valdés, M., Vicente, V., Marín, F., Lip, G.Y., Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation (2012) Circ Arrhythm Electrophysiol, 5, pp. 312-318
Lane, D.A., Lip, G.Y.H., Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation (2012) Circulation, 126, pp. 860-865
Friberg, L., Rosenqvist, M., Lip, G., Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation cohort study (2012) Circulation, 125, pp. 2298-2307
Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G., Healey, J.S., Yusuf, S., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range (2008) Circulation, 118, pp. 2029-2037. , ACTIVE W Investigators
Gallagher, A.M., Setakis, E., Plumb, J.M., Clemens, A., Van Staa, T.P., Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients (2011) Thromb Haemost, 106, pp. 968-977
Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., Pais, P., Connolly, S.J., Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial (2010) Lancet, 376, pp. 975-983. , RE-LY investigators
Morgan, C.L., McEwan, P., Tukiendorf, A., Robinson, P.A., Clemens, A., Plumb, J.M., Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control (2009) Thromb Res, 124, pp. 37-41
Ahrens, I., Lip, G.Y., Peter, K., New oral anticoagulant drugs in cardiovascular disease (2010) Thromb Haemost, 104, pp. 49-60
Ruff, C.T., Giugliano, R.P., Antman, E.M., Crugnale, S.E., Bocanegra, T., Mercuri, M., Hanyok, J., Braunwald, E., Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48 (2010) Am Heart J, 160, pp. 635-641
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Wallentin, L., Dabigatran vs. warfarin in patients with atrial fibrillation (2009) N Engl J Med, 361, pp. 1139-1151. , RE-LY Steering Committee and Investigators
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Reilly, P.A., Wallentin, L., Newly identified events in the RE-LY trial (2010) N Engl J Med, 363, pp. 1875-1876
Hohnloser, S.H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Eikelboom, J., Connolly, S.J., Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial (2012) Circulation, 125, pp. 669-676
Oldgren, J., Alings, M., Darius, H., Diener, H.C., Eikelboom, J., Ezekowitz, M.D., Kamensky, G., Connolly, S.J., Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial (2011) Ann Intern Med, 155, pp. 660-667. , RE-LY Investigators
Ezekowitz, M.D., Wallentin, L., Connolly, S.J., Parekh, A., Chernick, M.R., Pogue, J., Aikens, T.H., Yusuf, S., Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation (2010) Circulation, 122, pp. 2246-2253. , RE-LY Steering Committee and Investigators
Uchino, K., Hernandez, A.V., Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials (2012) Arch Intern Med, 172, pp. 397-402
Lip, G.Y., Lane, D.A., Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? (2010) Am J Med, 123, pp. 785-789
Lip, G.Y.H., Larsen, T.B., Skjoth, F., Rasmussen, L.H., Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation (2012) J Am Coll Cardiol, 60, pp. 738-746
Freeman, J.V., Zhu, R.P., Owens, D.K., Garber, A.M., Hutton, D.W., Go, A.S., Wang, P.J., Turakhia, M.P., Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation (2011) Ann Intern Med, 154, pp. 1-11
Sorensen, S.V., Kansal, A.R., Connolly, S., Peng, S., Linnehan, J., Bradley-Kennedy, C., Plumb, J.M., Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective (2011) Thromb Haemost, 105, pp. 908-919
Pink, J., Lane, S., Pirmohamed, M., Hughes, D.A., Dabigatran etexilate vs. warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses (2011) BMJ, 343, pp. d6333
Shah, S.V., Gage, B.F., Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation (2011) Circulation, 123, pp. 2562-2570
Banerjee, A., Lane, D.A., Torp-Pedersen, C., Lip, G.Y., Net clinical benefit of new oral anticoagulants (dabigatran rivaroxaban apixaban) vs. no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study (2012) Thromb Haemost, 107, pp. 584-589
Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., Dogne, J.M., Impact of dabigatran on a large panel of routine or specific coagulation assays (2012) Thromb Haemost, 107, pp. 985-997. , Laboratory recommendations for monitoring of dabigatran etexilate
Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.H., Wienen, W., Feuring, M., Clemens, A., Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010) Thromb Haemost, 103, pp. 1116-1127
Huisman, M.V., Lip, G.Y., Diener, H.C., Brueckmann, M., Van Ryn, J., Clemens, A., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice (2012) Thromb Haemost, 107, pp. 838-847
Tripodi, A., Measuring the anticoagulant effect of direct factor Xa inhibitors Is the anti-Xa assay preferable to the prothrombin time test? (2011) Thromb Haemost, 105, pp. 735-736
Barrett, Y.C., Wang, Z., Frost, C., Shenker, A., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay (2010) Thromb Haemost, 104, pp. 1263-1271
Pengo, V., Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Manotti, C., Italian federation of thrombosis centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) (2011) Thromb Haemost, 106, pp. 868-876
Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R., Levi, M., Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects (2011) Circulation, 124, pp. 1573-1579
Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J.L., Pernod, G., Effect of nonspecific reversal agents on anticoagulant activity of dabigatran , rivaroxaban A randomised crossover ex vivo study in healthy volunteers (2012) Thromb Haemost, 108, pp. 217-224
Sié, P., Samama, C.M., Godier, A., Rosencher, N., Steib, A., Llau, J.V., Van Der Linden, P., Gouin-Thibault, I., French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors (2011) Arch Cardiovasc Dis, 104, pp. 669-676. , Albaladejo P
Working Group on Perioperative Haemostasis Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis
Omran, H., Bauersachs, R., Rubenacker, S., Goss, F., Hammerstingl, C., The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation Results from the national multicentre BNK Online bRiDging REgistRy (BORDER) (2012) Thromb Haemost, 108, pp. 65-73
Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., Yang, S., Chernick, M., Aikens, T.H., Flaker, G., Connolly, S.J., Dabigatran vs. warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion (2011) Circulation, 123, pp. 131-136
Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., The use of dabigatran immediately after atrial fibrillation ablation (2011) J Cardiovasc Electrophysiol, 23, pp. 264-268
Lakkireddy, D., Reddy, Y.M., Di Biase, L., Vanga, S.R., Santangeli, P., Swarup, V., Pimentel, R., Natale, A., Feasibility and safety of dabigatran vs. warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial Fibrillation results from a multicenter prospective registry (2012) J Am Coll Cardiol, 59, pp. 1168-1174
Eikelboom, J.W., Wallentin, L., Connolly, S.J., Ezekowitz, M., Healey, J.S., Oldgren, J., Yang, S., Yusuf, S., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial (2011) Circulation, 123, pp. 2363-2372
Ruiz-Nodar, J.M., Marín, F., Roldán, V., Valencia, J., Manzano-Fernández, S., Caballero, L., Hurtado, J.A., Lip, G.Y., Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? (2012) Circ Cardiovasc Interv, 5, pp. 459-466
Lip, G.Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J.K., Cuisset, T., Kirchhof, P., Marín, F., Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting (2010) Eur Heart J, 31, pp. 1311-1318. , Consensus Document of European Society of Cardiology Working Group on Thrombosis
Huber, K., Airaksinen, K.J., Cuisset, T., Marin, F., Rubboli, A., Lip, G.Y., Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe (2011) Thromb Haemost, 106, pp. 569-571
Faxon, D.P., Eikelboom, J.W., Berger, P.B., Holmes, D.R., Bhatt, D.L., Moliterno, D.J., Becker, R.C., Angiolillo, D.J., Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective (2011) Thromb Haemost, 106, pp. 572-584
Mega, J.L., Braunwald, E., Wiviott, S.D., Bassand, J.P., Bhatt, D.L., Bode, C., Burton, P., Gibson, C.M., Rivaroxaban in patients with a recent acute coronary syndrome (2012) N Engl J Med, 366, pp. 9-19. , ATLAS ACS 2-TIMI 51 Investigators
Alexander, J.H., Lopes, R.D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D.L., Wallentin, L., Apixaban with antiplatelet therapy after acute coronary syndrome (2011) N Engl J Med, 365, pp. 699-708. , APPRAISE-2 Investigators
Matute, M.C., Masjuan, J., Egido, J.A., Fuentes, B., Simal, P., Díaz-Otero, F., Reig, G., Alonso De Leciñana, M., Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants (2012) Cerebrovasc Dis, 33, pp. 231-239
Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Prostran, M.S., Lip, G.Y., Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: The belgrade atrial fibrillation study (2012) Circ Arrhythm Electrophysiol, 5, pp. 319-326
Singer, D.E., Chang, Y., Fang, M.C., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., Go, A.S., The net clinical benefit of warfarin anticoagulation in atrial fibrillation (2009) Ann Intern Med, 151, pp. 297-305
De Caterina, R., Connolly, S.J., Pogue, J., Chrolavicius, S., Budaj, A., Morais, J., Renda, G., Yusuf, S., Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: Insights from ACTIVE-W (2010) Eur Heart J, 31, pp. 2133-2140
Hylek, E.M., D'Antonio, J., Evans-Molina, C., Shea, C., Henault, L.E., Regan, S., Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation (2006) Stroke, 37, pp. 1075-1080
Fox, K.A., Piccini, J.P., Wojdyla, D., Becker, R.C., Halperin, J.L., Nessel, C.C., Paolini, J.F., Califf, R.M., Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment (2011) Eur Heart J, 32, pp. 2387-2394
Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., Pfeffer, M., Yusuf, S., Clopidogrel plus aspirin vs. oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial (2006) Lancet, 367, pp. 1903-1912
Epstein, A.E., Relationships between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study (2004) Circulation, 109 (12), pp. 1509-1513. , DOI 10.1161/01.CIR.0000121736.16643.11
Klein, A.L., Grimm, R.A., Murray, R.D., Apperson-Hansen, C., Asinger, R.W., Black, I.W., Davidoff, R., Stoddard, M.F., Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation (2001) New England Journal of Medicine, 344 (19), pp. 1411-1420. , DOI 10.1056/NEJM200105103441901
Cox, J.L., Cardiac surgery for arrhythmias (2004) Journal of Cardiovascular Electrophysiology, 15 (2), pp. 250-262. , DOI 10.1046/j.1540-8167.2004.03656.x
Bayard, Y.L., Omran, H., Neuzil, P., Thuesen, L., Pichler, M., Rowland, E., Ramondo, A., Sievert, H., PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: Results from the European PLAATO study (2010) Euro Intervention, 6, pp. 220-226
Park, J.W., Bethencourt, A., Sievert, H., Santoro, G., Meier, B., Walsh, K., Lopez-Minquez, J.R., Leithäuser, B., Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: Initial European experience (2011) Catheter Cardiovasc Interv, 77, pp. 700-706
Holmes, D.R., Reddy, V.Y., Turi, Z.G., Doshi, S.K., Sievert, H., Buchbinder, M., Mullin, C.M., Sick, P., Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised noninferiority trial (2009) Lancet, 374, pp. 534-542
Whitlock, R.P., Healey, J.S., Connolly, S.J., Left atrial appendage occlusion does not eliminate the need for warfarin (2009) Circulation, 120, pp. 1927-1932. , discussion 32
Dawson, A.G., Asopa, S., Dunning, J., Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? (2010) Interact Cardiovasc Thorac Surg, 10, pp. 306-311
Reddy, V.Y., Holmes, D., Doshi, S.K., Neuzil, P., Kar, S., Safety of percutaneous left atrial appendage closure: Results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry (2011) Circulation, 123, pp. 417-424
Roy, D., Rowe, B.H., Stiell, I.G., Coutu, B., Ip, J.H., Phaneuf, D., Lee, J., Beatch, G.N., A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation (2004) Journal of the American College of Cardiology, 44 (12), pp. 2355-2361. , DOI 10.1016/j.jacc.2004.09.021, PII S0735109704018388
Roy, D., Pratt, C.M., Torp-Pedersen, C., Wyse, D.G., Toft, E., Juul-Moller, S., Nielsen, T., Camm, A.J., Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial (2008) Circulation, 117 (12), pp. 1518-1525. , DOI 10.1161/CIRCULATIONAHA.107.723866, PII 0000301720080325000006
Pratt, C.M., Roy, D., Torp-Pedersen, C., Wyse, D.G., Toft, E., Juul-Moller, S., Retyk, E., Drenning, D.H., Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation (2010) Am J Cardiol, 106, pp. 1277-1283. , Atrial Arrhythmia Conversion Trial (ACT-III) Investigators
Kowey, P.R., Dorian, P., Mitchell, L.B., Pratt, C.M., Roy, D., Schwartz, P.J., Sadowski, J., Toft, E., Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial (2009) Circ Arrhythm Electrophysiol, 2, pp. 652-659. , Atrial Arrhythmia Conversion Trial Investigators
Stiell, I.G., Roos, J.S., Kavanagh, K.M., Dickinson, G., A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm (2010) Am Heart J, 159, pp. 1095-1101
Camm, A.J., Capucci, A., Hohnloser, S.H., Torp-Pedersen, C., Van Gelder, I.C., Mangal, B., Beatch, G., A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation (2011) J Am Coll Cardiol, 57, pp. 313-321. , AVRO Investigators
Kynapid, , FDA. Briefing materials for the Cardiovascular and Renal Drugs Advisory Committee December 11, 2007 vernakalant hydrochloride injection NDA 22-034. Astellas Pharma US, Inc
Buccelletti, F., Iacomini, P., Botta, G., Marsiliani, D., Carroccia, A., Gentiloni Silveri, N., Franceschi, F., Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: Systematic review and meta-analysis (2011) J Clin Pharmacol
Bash, L.D., Buono, J.L., Davies, G.M., Martin, A., Fahrbach, K., Phatak, H., Avetisyan, R., Mwamburi, M., Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation (2012) Cardiovasc Drugs Ther, 26, pp. 167-179
Torp-Pedersen, C., Camm, A.J., Butterfield, N.N., Dickinson, G., Beatch, G.N., Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease Int J Cardiol., , Published online 21 November 2011. doi.org/10.1016/j.ijcard.2011 10.108
Camm, A.J., Toft, E., Torp-Pedersen, C., Vijayaraman, P., Juul-Moller, S., Ip, J., Beatch, G.N., Wyse, D.G., Efficacy and safety of vernakalant in patients with atrial flutter: A randomized, double-blind, placebocontrolled trial (2012) Europace, 14, pp. 804-809. , Scene 2 Investigators
Slavik, R.S., Tisdale, J.E., Borzak, S., Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence (2001) Progress in Cardiovascular Diseases, 44 (2), pp. 121-152. , DOI 10.1053/pcad.2001.26966
Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K., Vanderlugt, J.T., Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation (1996) Circulation, 94, pp. 1613-2152. , Ibutilide Repeat Dose Study Investigators
Volgman, A.S., Carberry, P.A., Stambler, B., Lewis, W.R., Dunn, G.H., Perry, K.T., Vanderlugt, J.T., Kowey, P.R., Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation (1998) Journal of the American College of Cardiology, 31 (6), pp. 1414-1419. , DOI 10.1016/S0735-1097(98)00078-3, PII S0735109798000783
Vos, M.A., Golitsyn, S.R., Stangl, K., Ruda, M.Y., Van Wijk, L., Harry, J.D., Perry, K.T., Wellens, H.J.J., Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation (1998) Heart, 79 (6), pp. 568-575
Savelieva, I., Kakouros, N., Kourliouros, A., Camm, A.J., Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines Part I: Primary prevention (2011) Europace, 13, pp. 308-328
Savelieva, I., Kakouros, N., Kourliouros, A., Camm, A.J., Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines Part II: Secondary prevention (2011) Europace, 13, pp. 610-625
Yamashita, T., Inoue, H., Okumura, K., Kodama, I., Aizawa, Y., Atarashi, H., Ohe, T., Ogawa, S., Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study) (2011) Europace, 13, pp. 473-479. , J-RHYTHM II Investigators
Bianconi, L., Calò, L., Mennuni, M., Santini, L., Morosetti, P., Azzolini, P., Barbato, G., Romano, P., Santini M. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: A randomized, double-blind, multicentre study (2011) Europace, 13, pp. 174-181
Kowey, P.R., Reiffel, J.A., Ellenbogen, K.A., Naccarelli, G.V., Pratt, C.M., Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial (2010) JAMA, 304, pp. 2363-2372
Lafuente-Lafuente, C., Mouly, S., Longas-Tejero, M.A., Mahe, I., Bergmann, J.F., Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials (2006) Arch Intern Med, 166, pp. 719-728
Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., Reynolds, M., Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation (2011) Europace, 13, pp. 329-345
Piccini, J.P., Hasselblad, V., Peterson, E.D., Washam, J.B., Califf, R.M., Kong, D.F., Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation (2009) J Am Coll Cardiol, 54, pp. 1089-1095
Sullivan, S.D., Orme, M.E., Morais, E., Mitchell, S.A., Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis (2012) Int J Cardiol, , Published online 31 March doi.org/10.1016/j.ijcard.2012.03.070
Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Breithardt, G., Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial (2012) Lancet, 380, pp. 238-246
Ahmed, S., Rienstra, M., Crijns, H.J., Links, T.P., Wiesfeld, A.C., Hillege, H.L., Bosker, H.A., Van Gelder, I.C., Continuous vs. episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial (2008) JAMA, 300, pp. 1784-1792. , CONVERT Investigators
Connolly, S.J., Evidence-based analysis of amiodarone efficacy and safety (1999) Circulation, 100 (19), pp. 2025-2034
Hohnloser, S.H., Crijns, H.J., Van Eickels, M., Gaudin, C., Page, R.L., Torp-Pedersen, C., Connolly, S.J., Effect of dronedarone on cardiovascular events in atrial fibrillation (2009) N Engl J Med, 360, pp. 668-678. , ATHENA Investigators
Kober, L., Torp-Pedersen, C., McMurray, J.J.V., Gotzsche, O., Levy, S., Crijns, H., Amlie, J., Carlsen, J., Increased mortality after dronedarone therapy for severe heart failure (2008) New England Journal of Medicine, 358 (25), pp. 2678-2687. , http://content.nejm.org/cgi/reprint/358/25/2678.pdf, DOI 10.1056/NEJMoa0800456
Duray, G.Z., Schmitt, J., Hohnloser, S.H., Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials (2010) J Cardiovasc Pharmacol Ther, 15 (SUPPL. 4), pp. 19S-23S
Camm, A.J., Savelieva, I., Atrial fibrillation: The rate vs. rhythm management controversy (2012) J R Coll Physicians Edinb, 42 (SUPPL. 18), pp. 23-34
Touboul, P., Brugada, J., Capucci, A., Crijns, H.J.G.M., Edvardsson, N., Hohnloser, S.H., Dronedarone for prevention of atrial fibrillation: A dose-ranging study (2003) European Heart Journal, 24 (16), pp. 1481-1487. , DOI 10.1016/S0195-668X(03)00321-X
Singh, B.N., Connolly, S.J., Crijns, H.J.G.M., Roy, D., Kowey, P.R., Capucci, A., Radzik, D., Hohnloser, S.H., Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter (2007) New England Journal of Medicine, 357 (10), pp. 987-999. , http://content.nejm.org/cgi/reprint/357/10/987.pdf, DOI 10.1056/NEJMoa054686
Davy, J.M., Herold, M., Hoglund, C., Timmermans, A., Alings, A., Radzik, D., Van Kempen, L., Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study (2008) Am Heart J, 156, pp. e1-e9. , 527
Le Heuzey, J.Y., De Ferrari, G.M., Radzik, D., Santini, M., Zhu, J., Davy, J.M., A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone vs. amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study (2010) J Cardiovasc Electrophysiol, 21, pp. 597-605
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., A randomized comparison of radiofrequency ablation and antiarrhythmia drug therapy as first line treatment in paroxysmal atrial fibrillation (2012) N Engl J Med, , in press
Morillo, C., Verma, A., Kuck, K.H., Radiofrequency ablation vs. Antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: (RAAFT 2): A randomized trial (2012) Heart Rhythm Society 2012 Scientific Sessions, , May 11 Boston, MA. Abstract LB02-1
Wazni, O.M., Marrouche, N.F., Martin, D.O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Natale, A., Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial (2005) Journal of the American Medical Association, 293 (21), pp. 2634-2640. , DOI 10.1001/jama.293.21.2634
Boersma, L.V., Castella, M., Van Boven, W., Berruezo, A., Yilmaz, A., Nadal, M., Sandoval, E., Mont, L., Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): A 2-center randomized clinical trial (2012) Circulation, 125, pp. 23-30
Pison, L., La Meir, M., Van Opstal, J., Blaauw, Y., Maessen, J., Crijns, H.J., Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation (2012) J Am Coll Cardiol, 60, pp. 54-61
Weerasooriya, R., Khairy, P., Litalien, J., MacLe, L., Hocini, M., Sacher, F., Lellouche, N., Jais, P., Catheter ablation for atrial fibrillation are results maintained at 5 years of follow-up? (2011) J Am Coll Cardiol, 57, pp. 160-166
Ouyang, F., Tilz, R., Chun, J., Schmidt, B., Wissner, E., Zerm, T., Neven, K., Kuck, K.H., Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year followup (2010) Circulation, 122, pp. 2368-2377
Tzou, W.S., Marchlinski, F.E., Zado, E.S., Lin, D., Dixit, S., Callans, D.J., Cooper, J.M., Gerstenfeld, E.P., Long-term outcome after successful catheter ablation of atrial fibrillation (2010) Circ Arrhythm Electrophysiol, 3, pp. 237-242
Arya, A., Hindricks, G., Sommer, P., Huo, Y., Bollmann, A., Gaspar, T., Bode, K., Piorkowski, C., Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients (2010) Europace, 12, pp. 173-180
Oral, H., Knight, B.P., Ozaydn, M., Tada, H., Chugh, A., Hassan, S., Scharf, C., Morady, F., Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation (2002) Journal of the American College of Cardiology, 40 (1), pp. 100-104. , DOI 10.1016/S0735-1097(02)01939-3, PII S0735109702019393
Lellouche, N., Jais, P., Nault, I., Wright, M., Bevilacqua, M., Knecht, S., Matsuo, S., Haissaguerre, M., Early recurrences after atrial fibrillation ablation: Prognostic value and effect of early reablation (2008) Journal of Cardiovascular Electrophysiology, 19 (6), pp. 599-605. , DOI 10.1111/j.1540-8167.2008.01188.x
Pokushalov, E., Romanov, A., Corbucci, G., Bairamova, S., Losik, D., Turov, A., Shirokova, N., Steinberg, J.S., Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? (2012) Heart Rhythm, , Published online ahead of print 23 March doi.org/10.1016/j.hrthm.2012.03. 047
Medi, C., Sparks, P.B., Morton, J.B., Kistler, P.M., Halloran, K., Rosso, R., Vohra, J.K., Kalman, J.M., Pulmonary vein antral isolation for paroxysmal atrial fibrillation: Results from long-term follow-up (2011) J Cardiovasc Electrophysiol, 22, pp. 137-141
Lee, G., Sparks, P.B., Morton, J.B., Kistler, P.M., Vohra, J.K., Medi, C., Rosso, R., Kalman, J.M., Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: Results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center (2011) J Cardiovasc Electrophysiol, 22, pp. 163-168
Arbelo, E., Brugada, J., Hindricks, G., Maggioni, A., Tavazzi, L., Vardas, P., Anselme, F., Trines, S., ESC-EURObservational research programme: The atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association (2012) Europace, 14, pp. 1094-1103. , on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators
Hoyt, H., Bhonsale, A., Chilukuri, K., Alhumaid, F., Needleman, M., Edwards, D., Govil, A., Spragg, D.D., Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors (2011) Heart Rhythm, 8, pp. 1869-1874
Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.H., Biganzoli, E., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation (2010) Circ Arrhythm Electrophysiol, 3, pp. 32-38
Shah, R.U., Freeman, J.V., Shilane, D., Wang, P.J., Go, A.S., Hlatky, M.A., Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation (2012) J Am Coll Cardiol, 59, pp. 143-149
Herrera Siklódy, C., Deneke, T., Hocini, M., Lehrmann, H., Shin, D.I., Miyazaki, S., Henschke, S., Arentz, T., Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: Comparison of different atrial fibrillation ablation technologies in a multicenter study (2011) J Am Coll Cardiol, 58, pp. 681-688
Di Biase, L., Burkhardt, J.D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G.J., Lakkireddy, D., Natale, A., Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio (2010) Circulation, 121, pp. 2550-2556
Haeusler, K.G., Kirchhof, P., Endres, M., Left atrial catheter ablation and ischemic stroke (2012) Stroke, 43, pp. 265-270
Gaita, F., Leclercq, J.F., Schumacher, B., Scaglione, M., Toso, E., Halimi, F., Schade, A., Blandino, A., Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: Comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon (2011) J Cardiovasc Electrophysiol, 22, pp. 961-968
Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A.J., Cappato, R., Cosio, F., Breithardt, G., Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' (2009) Europace, 11, pp. 860-885
Van Gelder, I.C., Haegeli, L.M., Brandes, A., Heidbuchel, H., Aliot, E., Kautzner, J., Szumowski, L., Kirchhof, P., Rationale and current perspective for early rhythm control therapy in atrial fibrillation (2011) Europace, 13, pp. 1517-1525
Schmidt, M., Segerson, N.M., Marschang, H., Akoum, N., Rittger, H., Clifford, S.M., Brachmann, J., Marrouche, N.F., Atrial fibrillation ablation in patients with therapeutic international normalized ratios (2009) Pacing Clin Electrophysiol, 32, pp. 995-999
Page, S.P., Siddiqui, M.S., Finlay, M., Hunter, R.J., Abrams, D.J., Dhinoja, M., Earley, M.J., Schilling, R.J., Catheter ablation for atrial fibrillation on uninterrupted warfarin can it be done without echo guidance? (2011) J Cardiovasc Electrophysiol, 22, pp. 265-270
Gautam, S., John, R.M., Stevenson, W.G., Jain, R., Epstein, L.M., Tedrow, U., Koplan, B.A., Michaud, G.F., Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation (2011) J Cardiovasc Electrophysiol, 22, pp. 248-254
Gopinath, D., Lewis, W.R., Di Biase, L., Natale, A., Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations (2011) J Cardiovasc Electrophysiol, 22, pp. 236-239
Hakalahti, A., Uusimaa, P., Ylitalo, K., Raatikainen, M.J., Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment (2011) Europace, 13, pp. 640-645
Latchamsetty, R., Gautam, S., Bhakta, D., Chugh, A., John, R.M., Epstein, L.M., Miller, J.M., Jongnarangsin, K., Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin (2011) Heart Rhythm, 8, pp. 805-808
Calkins, H., Kuck, K.H., Cappato, R., Brugada, J., Camm, A.J., Chen, S.A., Crijns, H.J., Wilber, D., 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design (2012) Europace, 14, pp. 528-606
Kirchhof, P., Lip, G.Y., Van Gelder, I.C., Bax, J., Hylek, E., Kaab, S., Schotten, U., Camm, A.J., Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options-A report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference (2012) Europace, 14, pp. 8-27
Van Gelder, I.C., Haegeli, L.M., Brandes, A., Heidbuchel, H., Aliot, E., Kautzner, J., Szumowski, L., Kirchhof, P., Rationale and current perspective for early rhythm control therapy in atrial fibrillation (2011) Europace, 13, pp. 1517-1525
Pappone, C., Vicedomini, G., Augello, G., Manguso, F., Saviano, M., Baldi, M., Petretta, A., Santinelli, V., Radiofrequency catheter ablation and antiarrhythmic drug therapy: A prospective, randomized, 4-year follow-up trial: The APAF study (2011) Circ Arrhythm Electrophysiol, 4, pp. 808-814
Tanner, H., Makowski, K., Roten, L., Seiler, J., Schwick, N., Müller, C., Fuhrer, J., Delacrétaz, E., Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors (2011) Europace, 13, pp. 646-653
Wazni, O., Wilkoff, B., Saliba, W., Catheter ablation for atrial fibrillation (2011) N Engl J Med, 365, pp. 2296-2304
Calkins, H., Reynolds, M.R., Spector, P., Sondhi, M., Xu, Y., Martin, A., Williams, C.J., Sledge, I., Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses (2009) Circ Arrhythm Electrophysiol, 2, pp. 349-361
Wilber, D.J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., MacLe, L., Thermocool, A.F., Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial (2010) JAMA, 303, pp. 333-340. , Trial Investigators
Haissaguerre, M., Jais, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Clementy, J., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins (1998) New England Journal of Medicine, 339 (10), pp. 659-666. , DOI 10.1056/NEJM199809033391003
Leong-Sit, P., Roux, J.F., Zado, E., Callans, D.J., Garcia, F., Lin, D., Marchlinski, F.E., Gerstenfeld, E.P., Antiarrhythmics after ablation of atrial fibrillation (5A Study): Six-month follow-up study (2011) Circ Arrhythm Electrophysiol, 4, pp. 11-14
